These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 9122231)

  • 1. alpha-Galactosidase A deficient mice: a model of Fabry disease.
    Ohshima T; Murray GJ; Swaim WD; Longenecker G; Quirk JM; Cardarelli CO; Sugimoto Y; Pastan I; Gottesman MM; Brady RO; Kulkarni AB
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2540-4. PubMed ID: 9122231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
    Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
    Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
    Fan JQ; Ishii S; Asano N; Suzuki Y
    Nat Med; 1999 Jan; 5(1):112-5. PubMed ID: 9883849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
    Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
    Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease.
    Yoshimitsu M; Higuchi K; Fan X; Takao S; Medin JA; Tei C; Takenaka T
    Mol Biol Rep; 2011 Jun; 38(5):3145-52. PubMed ID: 20131008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
    Labilloy A; Youker RT; Bruns JR; Kukic I; Kiselyov K; Halfter W; Finegold D; do Monte SJ; Weisz OA
    Mol Genet Metab; 2014 Feb; 111(2):184-92. PubMed ID: 24215843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector.
    Medin JA; Tudor M; Simovitch R; Quirk JM; Jacobson S; Murray GJ; Brady RO
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7917-22. PubMed ID: 8755577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
    Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
    Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
    Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
    Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
    Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.
    Ohshima T; Schiffmann R; Murray GJ; Kopp J; Quirk JM; Stahl S; Chan CC; Zerfas P; Tao-Cheng JH; Ward JM; Brady RO; Kulkarni AB
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6423-7. PubMed ID: 10339603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
    Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
    J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.
    Ioannou YA; Zeidner KM; Gordon RE; Desnick RJ
    Am J Hum Genet; 2001 Jan; 68(1):14-25. PubMed ID: 11115376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer.
    Park J; Murray GJ; Limaye A; Quirk JM; Gelderman MP; Brady RO; Qasba P
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3450-4. PubMed ID: 12624185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
    Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
    Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High overexpression of the human alpha-galactosidase A gene driven by its promoter in transgenic mice: implications for the treatment of Fabry disease.
    Ashley GA; Desnick RJ; Gordon RE; Gordon JW
    J Investig Med; 2002 May; 50(3):185-92. PubMed ID: 12033283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice.
    Pagant S; Huston MW; Moreira L; Gan L; St Martin S; Sproul S; Holmes MC; Meyer K; Wechsler T; Desnick RJ; Yasuda M
    Mol Ther; 2021 Nov; 29(11):3230-3242. PubMed ID: 33775910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
    Choi JO; Lee MH; Park HY; Jung SC
    J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.